HKT-500 in Adult Patients With Osteoarthritis (OA) Knee Pain

Phase 3

Completed

Brief Summary: Ketoprofen in a topical patch formulation has been demonstrated to be effective for treating mild to moderate pain caused by various musculoskeletal disorders.

Detailed Description: The objective of this study is to demonstrate the short-term multiple dose efficacy and safety of HKT-500 in subjects with pain caused by mild to moderate osteoarthritis of the knee. The goal of the study is to gather additional information about the analgesic efficacy and safety of repeated, 24-hour applications of 2 HKT-500 patches per knee for a total of 28 days in subjects with pain caused by mild to moderate osteoarthritis of the knee.

Recruitment & Eligibility

Inclusion Criteria

man or woman ≥45 years of age.
clinical diagnosis of unilateral or bilateral OA of the knee
taking an NSAID or acetaminophen on a regular basis and has a history of knee pain amelioration with NSAID or acetaminophen use.
mild to moderate OA of the knee at the screening visit
subject exhibits an arthritis "flare" in the target knee within 7 days day of withdrawing from a NSAID or acetaminophen.
subject understands that treatment will be administered on an inpatient basis.
subject is capable of understanding and complying with the protocol and has signed the informed consent document.

Exclusion Criteria

subject is a woman of childbearing potential who has a positive urine pregnancy test, is lactating, or who is not surgically sterile
subject has symptoms that are attributable to primary inflammatory diseases of the joint
subject has unstable knees including a history of the knee catching or giving way or physical examination evidence of instability
subject has arthropathies that occur in conjunction with systemic diseases
subject has a chronic pain condition
subject is grossly obese
subject has a history of knee surgery within the past 12 months or arthroscopy within the past 6 months.
subject has a history of osteotomies.
subject is not willing to discontinue the use of NSAIDs, acetaminophen or other prohibited treatments
subject used opioids for OA pain within 1 month

Arm && Interventions

Group	Intervention	Description
Ketoprofen Patch	ketoprofen Patch	Treatment with experimental drug
Placebo Patch	Placebo Patch	Treatment with placebo drug

Primary Outcome Measures

Name	Time	Method
Change from the baseline of the WOMAC pain subscale score at Visit 6 (Day 14 ± 2 days)	14 days ± 2 days

Secondary Outcome Measures

Name	Time	Method
WOMAC: Change from the baseline of the pain subscale score at Visit 5 (Day 7 ±1 day), Visit 7 (Day 21 ±3 days) and Visit 8 (Day 28 ±3 days)	28 days (±3 days)
WOMAC: Change from the baseline of the subscale scores for stiffness and physical function at Visit 5, Visit 6, Visit 7 and Visit 8	28 days (±3 days)
WOMAC: Change from the baseline of the composite score at Visit 5, Visit 6, Visit 7 and Visit 8	28 days (±3 days)
Pain Intensity differences at rest, on motion and of overall assessment using a VAS scale at each follow-up assessments time point through Day 28.	28 days
Subject's Global Assessment at Visit 6 and Visit 8	28 days (±3 days)
Investigator's Global Assessment at Visit 6 and Visit 8	28 days (±3 days)